We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

News · September 30, 2021

ESMO 2021: VESPER Trial Indicates Neoadjuvant Dose-Dense MVAC May be Practice-Impacting in Muscle Invasive Bladder Cancer.

Dose-dense MVAC did not improve 3-year PFS in all peri-operative therapy patients, but did improve PFS as neoadjuvant therapy

PracticeUpdate Editorial Team


Further Reading